601567 三星医疗
2025/06 - 中期
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入7,972,21413.93%14,600,47811,462,5089,098,2037,022,902
减:营业总成本6,798,03916.23%12,231,8939,763,0058,045,1076,520,178
    其中:营业成本5,662,48823.72%9,530,6477,575,0156,470,4775,241,357
               财务费用(114,664)-312.03%158,627(8,838)(14,853)88,302
               资产减值损失(37,258)155.39%(56,494)(12,987)(11,539)(13,066)
公允价值变动收益25,303-150.65%(172,769)116,975(107,481)103,697
投资收益119,397-7.14%229,188296,13784,951204,334
    其中:对联营企业和合营企业的投资收益109,9746.71%194,975230,272189,892134,226
营业利润1,381,8335.04%2,585,1332,270,4521,152,349851,227
利润总额1,401,2263.13%2,672,5572,262,0671,152,047846,813
减:所得税费用186,312-8.91%399,319341,263187,042139,204
净利润1,214,9135.27%2,273,2371,920,804965,005707,609
减:非控股权益(14,819)-462.50%13,72017,10216,88917,567
股东净利润1,229,7326.93%2,259,5181,903,702948,116690,043

市场价值指针
每股收益 (元) *0.8707.41%1.6001.3500.6700.500
每股派息 (元) *0.485--0.8900.6500.3500.320
每股净资产 (元) *8.6219.52%8.5627.7946.7296.333
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容